eef1akmt1 Antibody

What is eEF1A and why is its methylation important in research?

eEF1A (Elongation factor 1-alpha) is a critical translation elongation factor that catalyzes the GTP-dependent binding of aminoacyl-tRNA to the A-site of ribosomes during the elongation phase of protein synthesis. It functions within a complex where it interacts with other molecules to ensure accurate and efficient codon-anticodon pairing on the ribosome . eEF1A exhibits a mass of approximately 50 kDa and shows high expression in various tissues, particularly liver and neuronal tissues .

The methylation status of eEF1A is increasingly recognized as an important regulatory mechanism that influences protein synthesis and may play roles in aging and disease processes. Recent research has demonstrated that methylation levels of eEF1A decline in aged tissues, suggesting a potential regulatory role in age-related biological processes . Understanding eEF1A methylation provides insights into translation regulation mechanisms that extend beyond basic protein synthesis to broader cellular functions.

What are the key differences between eEF1A1 and eEF1A2 isoforms?

eEF1A exists in two main isoforms in humans: eEF1A1 and eEF1A2, which have distinct tissue distribution patterns:

• eEF1A1: This isoform is broadly expressed in brain, placenta, lung, liver, kidney, and pancreas . It represents the more ubiquitous form of the protein.

• eEF1A2: Expression is more restricted, primarily found in brain, heart, and skeletal muscle .

These tissue-specific expression patterns are significant when designing experiments, as antibody sensitivity may vary between the isoforms. Some antibodies may have preferential recognition of eEF1A1 methylation compared to eEF1A2, which is an important consideration when studying tissues like skeletal muscle where eEF1A2 predominates .

What types of antibodies are available for studying eEF1A and its methylated forms?

Several types of antibodies are available for eEF1A research:

• General eEF1A antibodies: These recognize total eEF1A protein regardless of post-translational modifications:

  • Rabbit polyclonal antibodies targeting specific regions (e.g., aa 250-350 in human EEF1A1)

  • Mouse monoclonal antibodies like clone F02/1E3 that detect the 50 kDa band in western blotting

• Methylation-specific antibodies: These selectively recognize specific methylation states at particular amino acid residues:

  • Antibodies targeting eEF1A-K36me3

  • Antibodies targeting eEF1A-K79me3

  • Antibodies targeting eEF1A-K165 methylation

These methylation-specific antibodies have demonstrated high specificity, with each antibody selectively recognizing its cognate epitope without cross-reacting with other methylation events on eEF1A or with histone and non-histone proteins .

How can I validate the specificity of eEF1A methylation-specific antibodies?

Validating antibody specificity is crucial for reliable experimental outcomes. Recommended validation approaches include:

• Peptide arrays: Test antibodies against arrays containing methyl-peptides covering different eEF1A sites and methylation states. A specific antibody should recognize only its cognate methyl-epitope .

• Knockdown experiments: Use CRISPR/Cas9 system to specifically knockdown individual eEF1A methyltransferases (KMTs). The band recognized by a methyl-specific antibody should be depleted upon knockdown of its cognate KMT .

• Cross-reactivity testing: Test antibodies against non-eEF1A methylated histone and nonhistone peptides to confirm they don't detect unrelated methylated proteins .

• Multiple detection methods: Validate antibody specificity using multiple techniques (western blotting, IHC, ICC) to ensure consistent performance across applications .

What are the optimal conditions for western blotting with eEF1A antibodies?

For optimal western blotting results with eEF1A antibodies, consider the following guidelines:

• Antibody dilutions:

  • For polyclonal antibodies: Typically 1:500-1:1,000

  • For monoclonal antibodies: Often 1:1000

• Sample preparation:

  • Use whole cell lysates for detecting total eEF1A protein

  • Ensure complete protein denaturation for optimal epitope exposure

  • Include phosphatase/protease inhibitors to preserve post-translational modifications

• Controls:

  • Include positive control samples (e.g., HEK293 cell lysate for anti-eEF1A1 antibodies)

  • Include methyltransferase knockdown samples as negative controls when possible

• Detection:

  • The expected molecular weight for eEF1A is approximately 50 kDa

  • Secondary antibody selection depends on the host species of the primary antibody (e.g., goat anti-mouse IgG:HRP for mouse monoclonal antibodies)

How can I design experiments to study crosstalk between different eEF1A methylation sites?

Investigating crosstalk between eEF1A methylation sites requires strategic experimental design:

• Targeted KMT knockdowns: Generate individual knockdowns of each eEF1A-specific methyltransferase (METTL13, METTL10, eEF1AKMT4, N6AMT2, METTL21B) and analyze how depletion of one enzyme affects methylation at other sites .

• Sequential immunoblotting: Probe the same membrane with different methyl-specific antibodies to detect changes in multiple methylation sites simultaneously.

• Mass spectrometry analysis: Perform MS analysis of eEF1A to quantitatively assess changes in methylation at multiple sites following single KMT knockdowns.

• Time-course experiments: Analyze the temporal dynamics of different methylation events to establish potential sequential relationships.

Research has already identified examples of crosstalk, such as:

• N6AMT2 depletion impacts eEF1AK36me3 levels

• METTL10 depletion affects eEF1AK79me3 levels

These observations suggest a coordinated regulatory network involving multiple eEF1A methylation events.

How can I use eEF1A methylation-specific antibodies to investigate aging biology?

Emerging evidence suggests eEF1A methylation levels decline in aged tissues . To investigate this phenomenon:

• Comparative tissue analysis:

  • Compare eEF1A methylation levels in young vs. aged tissues using methyl-specific antibodies

  • Analyze multiple tissues to identify tissue-specific changes in methylation patterns

• Functional consequences assessment:

  • Correlate changes in eEF1A methylation with alterations in protein synthesis rates

  • Evaluate impact on specific cellular processes like stress responses or protein quality control

• Intervention studies:

  • Test whether interventions that extend lifespan (caloric restriction, rapamycin) affect eEF1A methylation

  • Investigate whether modulating specific eEF1A KMTs can rescue age-related phenotypes

• Temporal dynamics:

  • Map the timeline of eEF1A methylation changes during aging

  • Determine whether changes precede or follow the onset of age-related functional decline

This research direction may provide insights into how protein synthesis regulation via eEF1A methylation contributes to aging biology .

What approaches can I use to study eEF1A methylation in response to cellular stress?

eEF1A methylation appears to be dynamic and responsive to cellular conditions . To study stress-induced changes:

• Nutrient stress experiments:

  • Compare eEF1A methylation levels under normal growth, serum starvation, and serum re-stimulation conditions

  • eEF1A-K165 methylation has been shown to dynamically change in response to nutrient conditions

• Oxidative stress analysis:

  • Expose cells to oxidative stressors and monitor changes in eEF1A methylation patterns

  • Correlate methylation changes with alterations in translation efficiency

• Heat shock response:

  • Investigate whether temperature stress alters eEF1A methylation status

  • Analyze potential roles in selective translation during stress

• Integrated 'omics approach:

  • Combine proteomics, ribosome profiling, and methylation analysis to build a comprehensive picture of how eEF1A methylation status influences translation programs under stress

What are the optimal protocols for using eEF1A antibodies in immunohistochemistry?

When using eEF1A antibodies for immunohistochemistry (IHC), consider these methodological guidelines:

• Antibody dilutions:

  • For polyclonal antibodies: Typically 1:50-1:200

  • Optimize dilutions for each tissue type and fixation method

• Tissue preparation:

  • Formalin-fixed paraffin-embedded (FFPE) tissues are suitable for many eEF1A antibodies

  • Use antigen retrieval methods to expose epitopes masked by fixation

• Tissue-specific considerations:

  • Be aware that eEF1A methylation stoichiometry may be modulated in a tissue-specific manner

  • In skeletal muscle, consider the predominant expression of eEF1A2 isoform and potentially lower total eEF1A levels

• Controls and validation:

  • Include tissue sections known to express high levels of eEF1A (e.g., liver, brain)

  • Consider using methyltransferase knockout or knockdown tissues as negative controls for methyl-specific antibodies

eEF1A antibodies have been successfully used for IHC in various tissues including mouse colon, skeletal muscle, and human pancreatic ductal adenocarcinoma samples .

How can I troubleshoot common issues when working with eEF1A and methylation-specific antibodies?

Common issues and troubleshooting approaches include:

• High background signal:

  • Increase blocking time or concentration

  • Try alternative blocking agents (BSA, normal serum, commercial blockers)

  • Increase antibody washing steps and duration

  • Optimize primary antibody concentration

• Low or no signal:

  • Check antibody reactivity with your species of interest

  • Ensure target protein is expressed in your sample

  • Optimize antigen retrieval methods

  • Consider alternative fixation protocols

  • For methylation detection, verify that the methyltransferase is expressed in your tissue/cell type

• Non-specific bands in western blot:

  • Increase blocking stringency

  • Use purified antibody preparations

  • Optimize antibody dilution and incubation conditions

  • Include appropriate positive and negative controls

• Cross-reactivity concerns:

  • Validate antibody specificity using peptide arrays or dot blot assays

  • Confirm results using alternative detection methods

  • Consider using genetic knockdown/knockout models as definitive controls

• Storage and handling:

  • Store antibodies according to manufacturer recommendations (typically -20°C for long-term storage)

  • For frequent use, store at 4°C for up to one month

  • Avoid repeated freeze-thaw cycles that can degrade antibody quality

What are the recommended applications and dilutions for commonly used eEF1A antibodies?

This table provides a starting point for assay optimization. The actual working concentration may vary and should be determined empirically for each specific application and experimental system .

What controls should I include when studying eEF1A methylation using specific antibodies?

Robust experimental design requires appropriate controls:

• Positive controls:

  • Cell lines known to express high levels of methylated eEF1A

  • Recombinant methylated peptides or proteins

  • Tissues with documented high expression (liver, neuronal tissues)

• Negative controls:

  • Methyltransferase knockout/knockdown samples

  • Competing peptides to demonstrate antibody specificity

  • Samples treated with general methylation inhibitors

• Technical controls:

  • Antibody isotype controls

  • Secondary antibody-only controls

  • Total eEF1A detection alongside methylated form detection

• Validation controls:

  • Multiple antibodies targeting the same modification

  • Orthogonal methods for detecting methylation (e.g., mass spectrometry)

  • Testing antibody specificity using peptide arrays or dot blot assays with various methylated and unmethylated peptides